Illumina

CA - HaywardDiagnostics1 H-1B visas (FY2023)

Focus: Illumina is a market-leading provider of genomic sequencing tools, research products, and molecular diagnostics for precision medicine across oncology, infectious diseases, and genetic testing. Founded in 1998 and headquartered in Hayward, CA, the company operates at significant scale with 152 active job openings across multiple functions.

Gastroenterology Neurology Ophthalmology Oncology

Profile data last refreshed 7h ago · AI intelligence enriched 2w ago

Open Jobs

5 recent layoff filings (12 mo) — 16 affected

1/14/2026 — 5200 Illumina Way San Diego CA 92122, CA · 1 affected · Layoff
1/14/2026 — 5200 Illumina Way San Diego CA 92122, CA · 4 affected · Layoff Amendment
12/22/2025 — 5200 Illumina Way San Diego CA 92122, CA · 1 affected · Layoff Amendment
+2 more

Source: state DOL filings via Big Local News

About Illumina

AI assessmentNot Hiring

No open roles listed right now. Follow Illumina to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

TruGenome Cardiovascular Disease Test

Cardiovascular Diseases

Growth

Clinical diagnostic test leveraging genomic risk assessment for preventive cardiovascular medicine.

Comprehensive Genomic Profiling

Solid Tumors

Help build intelligence for Illumina

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge next-generation sequencing (NGS) technology platform with expanding clinical applications across oncology, prenatal diagnostics, rare disease, and cardiovascular disease
Strong hiring momentum across engineering (43 roles) and commercial (39 roles), indicating growth trajectory and career progression opportunities
Diversified pipeline spanning 30 programs including Phase 3 assets (18F-MFBG for neuroblastoma) and clinical sequencing applications in high-impact therapeutic areas

Watch Out For

Limited pipeline visibility: majority of programs are research/diagnostic studies (phase not applicable) rather than traditional drug development, limiting exposure to traditional pharma development workflows
Minimal clinical-stage pipeline activity: only 6 programs in Phase 1-3, with only 1 Phase 3 program, suggesting lower near-term regulatory catalyst potential compared to traditional biotech

Generated by Claude from Illumina's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Oncology diagnostic platform enabling tumor sequencing and treatment selection across multiple cancer types.

COVIDSeq Test

SARS-CoV-2

Stable

NGS-based diagnostic assay for COVID-19 detection, demonstrating infectious disease diagnostic capability.

Pipeline & Clinical Trials

Ultrafast Whole Genome Sequencing for Childhood Cancer

Cancer Childhood

N/A

Clinical Trials (1)

NCT07201038Ultrafast Whole Genome Sequencing for Childhood Cancer

N/A

Diagnostic test for detection of SARS-CoV-2

SARS-CoV-2

N/A

Preimplantation Genetic Screening by NGS

Infertility

N/A

Clinical Trials (1)

NCT02268786Single Embryo TrAnsfeR of Euploid Embryo

N/A

Comprehensive genomic profiling

Solid Tumor

N/A

Clinical Trials (1)

NCT05058937A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre

N/A

Nipple aspirator

Breast Cancer

N/A

TruGenome Cardiovascular Disease test

Cardiovascular Diseases

N/A

Clinical Trials (1)

NCT05656183CardioSeq: Impact of WGS in Individuals With CVD

N/A

Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler

Acute Myeloid Leukemia (AML)

N/A

Confirmatory Testing

Spinal Muscular Atrophy

N/A

Non-intensive intervention

Diabetes Mellitus, Type 2

N/A

Clinical Trials (1)

NCT05372445Microbiome and Health Indicators in People With Obesity, Prediabetes and Type 2 Diabetes Undergoing a Lifestyle Intervention

N/A

Detection of Factor V Leiden G1691A and Factor II (Prothrombin) G20210A Point Mutations in DNA

Detection and Genotyping of Factor V and Factor II Point Mutations

N/A

Clinical Trials (1)

NCT00959504Detection of Factor V Leiden G1691A and Factor II (Prothrombin) G20210A Point Mutations in DNA

N/A

Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Mark

Preeclampsia

N/A

Clinical Trials (1)

NCT02808494Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers

N/A

Next Generation Sequencing

Leukemia

N/A

Clinical Trials (1)

NCT05046444Solving Riddles Through Sequencing

N/A

Genetic risk assessment

Coronary Artery Disease

N/A

Clinical Trials (1)

NCT05175651Prospective Electronic Polygenic Risk Study - Second Phase

N/A

Prospective Electronic Polygenic Risk Study

Coronary Artery Disease

N/A

Clinical Trials (1)

NCT05072275Prospective Electronic Polygenic Risk Study

N/A

A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gen

Breast Cancer

N/A

COVIDSeq Test

SARS-CoV-2

N/A

clinical whole genome sequencing

Rare Diseases

N/A

A Study Collecting Blood Samples From Pregnant Women to Aid in the Development of a Noninvasive Pren

Pregnancy

N/A

Clinical Trials (1)

NCT03620110A Study Collecting Blood Samples From Pregnant Women to Aid in the Development of a Noninvasive Prenatal Test

N/A

clinical Whole Genome Sequencing

Neurologic Deficits

N/A

Clinical Trials (1)

NCT04170985NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology

N/A

cfDNA analysis

Early Pregnancy Loss

N/A

Clinical Trials (1)

NCT04935138Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss

N/A

Whole-genome sequencing

Cerebral Palsy

N/A

Clinical Trials (1)

NCT05858268NeuralNET Cerebral Palsy Pilot Study

N/A

iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disorders

Genetic Disease

N/A

Clinical Trials (1)

NCT05049967iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disorders

N/A

Genome sequencing-based newborn screening

Early Onset Genetic Conditions With Near Complete Penetrance

N/A

Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormal

Post-natal Cytogenetics

N/A

Clinical Trials (1)

NCT01426308Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test

N/A

Collection of Whole Blood Specimens in Pregnant Women

Pregnancy Related

N/A

Clinical Trials (1)

NCT03590678Collection of Whole Blood Specimens in Pregnant Women

N/A

18F-mFBG for intravenous administration

Cardiovascular Diseases

Phase 1/2

Clinical Trials (1)

NCT04535193Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation

Phase 1/2

18F-MFBG

Parkinson Disease (PD)

Phase 2

Clinical Trials (1)

NCT0717628618F-mFBG Cardiac Uptake With Lewy Body Dementia

Phase 2

18F-metaFluorobenzylguanidine

Heart Failure

Phase 2

Clinical Trials (1)

NCT0696562118F-mFBG Imaging for Myocardial Sympathetic Innervation

Phase 2

18F-mFBG

Neuroblastoma

Phase 2

Clinical Trials (1)

NCT0623390318F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

Phase 2

18F-MFBG

Neuroblastoma

Phase 3

Clinical Trials (1)

NCT04724369Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 1998

Portfolio: 22 clinical trials

Top TAs: Oncology, Cardiovascular, Metabolic Diseases

H-1B (2023): 1 approval

Therapeutic Area Focus

5 pipeline

3 pipeline

1 pipeline

1 pipeline

1 pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (5)

2026-01-14

1 employees affected— 5200 Illumina Way San Diego CA 92122, CA

source

2026-01-14

4 employees affected— 5200 Illumina Way San Diego CA 92122, CA

source

Women's Health

1 pipeline

2025-12-22

1 employees affected— 5200 Illumina Way San Diego CA 92122, CA

source

2025-12-11

7 employees affected— San Diego, CA

source

2025-12-04

3 employees affected— 5200 Illumina Way San Diego CA 92122, CA

source

Source: state DOL filings, aggregated via Big Local News

No reported FDA warnings, WARN Act filings, or product shortages indicate stable operational footing with no immediate restructuring signals.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo